These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10376798)

  • 41. In vitro studies on mechanism of the "eclipse" of cell-mediated immunity in mice bearing advanced tumors.
    Youn JK; Le François D; Barski G
    J Natl Cancer Inst; 1973 Apr; 50(4):921-6. PubMed ID: 4735758
    [No Abstract]   [Full Text] [Related]  

  • 42. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
    Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
    Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and persistence of cytolytic T lymphocytes in regressing or progressing Moloney sarcomas.
    Gillespie GY; Russell SW
    Int J Cancer; 1978 Jan; 21(1):94-99. PubMed ID: 304846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of complement activation on tumor oxygenation during photodynamic therapy.
    Cecic I; Minchinton AI; Korbelik M
    Photochem Photobiol; 2007; 83(5):1049-55. PubMed ID: 17880499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells.
    Cecic I; Sun J; Korbelik M
    Photochem Photobiol; 2006; 82(2):558-62. PubMed ID: 16613513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemodynamic monitoring of Chlorin e6-mediated photodynamic therapy using diffuse optical measurements.
    Dong J; Toh HJ; Thong PS; Tee CS; Bi R; Soo KC; Lee K
    J Photochem Photobiol B; 2014 Nov; 140():163-72. PubMed ID: 25146878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC.
    van Geel IP; Oppelaar H; Marijnissen JP; Stewart FA
    Radiat Res; 1996 May; 145(5):602-9. PubMed ID: 8619026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-tumour cytotoxic effects mediated by minor and major cell populations of lymph nodes.
    Seeger RC; Owen JJ
    Nature; 1974 Nov; 252(5482):420-1. PubMed ID: 4547827
    [No Abstract]   [Full Text] [Related]  

  • 49. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors.
    de Vree WJ; Essers MC; Koster JF; Sluiter W
    Cancer Res; 1997 Jul; 57(13):2555-8. PubMed ID: 9205052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy.
    Cecic I; Stott B; Korbelik M
    Int Immunopharmacol; 2006 Aug; 6(8):1259-66. PubMed ID: 16782538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting efficacy of photodynamic therapy by real-time FDG-PET in a mouse tumour model.
    Cauchon N; Turcotte E; Lecomte R; Hasséssian HM; Lier JE
    Photochem Photobiol Sci; 2012 Feb; 11(2):364-70. PubMed ID: 22234417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide.
    Glaser M
    Cell Immunol; 1979 Dec; 48(2):339-45. PubMed ID: 228870
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunologic reactivity of lymphoid cells in tumors.
    Herberman RB; Holden HT; Varesio L; Taniyama T; Puccetti P; Kirchner H; Gerson J; White S; Keisari Y; Haskill JS
    Contemp Top Immunobiol; 1980; 10():61-78. PubMed ID: 6967800
    [No Abstract]   [Full Text] [Related]  

  • 54. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model.
    Baas P; Oppelaar H; Stavenuiter M; van Zandwijk N; Stewart FA
    Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):665-70. PubMed ID: 8226162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?
    Anzengruber F; Avci P; de Freitas LF; Hamblin MR
    Photochem Photobiol Sci; 2015 Aug; 14(8):1492-1509. PubMed ID: 26062987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of tumor immunity by photodynamic therapy.
    Korbelik M
    J Clin Laser Med Surg; 1996 Oct; 14(5):329-34. PubMed ID: 9612200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T cell-mediated immunity to oncornavirus-induced tumors. III. Specific and nonspecific suppression in tumor-bearing mice.
    Plater C; Debré P; Leclerc JC
    Eur J Immunol; 1981 Jan; 11(1):39-44. PubMed ID: 6452278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses.
    Watson GA; Lopez DM
    J Immunol; 1995 Sep; 155(6):3124-34. PubMed ID: 7673727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.